Valeant Pharmaceuticals International (Laval, Quebec) said that it has entered into a definitive agreement under which it will acquire all of the outstanding common stock of Solta Medical (Hayward, California) for $250 million. Valeant said that it will pay about $2.92 per share in cash, which represents a 40% premium to Solta's closing share price on Dec. 13, 2013, the last trading day prior to announcement, or a transaction value of approximately $250 million. Read More
